medigraphic.com
ISSN 1025-0255 (Electronic)

2016, Number 4

<< Back Next >>

AMC 2016; 20 (4)

Immunomodulatory anti-inflammatory effect of moxifloxacin as an adjunct in periodontal therapy

Ardila MCM, Bedoya GJ, Patiño GJE

Language: Spanish
References: 34
Page: 444-451
PDF size: 635.08 Kb.


ABSTRACT

Background: periodontitis is an infectious disease that occurs as a result of the interaction between microorganisms and some different reactions of the host to infection. The anti-inflammatory immunomodulatory function of antimicrobial drugs such as moxifloxacin can be a useful quality in the treatment of periodontitis.
Objective: to review the scientific literature related to the immunomodulatory effect of moxifloxacin.
Methods: a systematic review of research conducted in humans or human cells published in Medline-Pubmed, SciELO, LILACS and academic Google between 1996 and 2015 data was performed using the following terms in different combinations: moxifloxacin, immunomodulation, cytokines, interleukins and tumor necrosis factor. Case series, duplicate results due to combinations of search terms, missing data, letters to the editor and historical revisions, were excluded.
Development: a total of nine studies showed decreased release of the interleukins 1β, 6, 8, while five studies showed inhibition. Similarly, three publications showed inhibition of tumor necrosis factor α and three arranged reduction of their release.
Conclusions: moxifloxacin, besides its effectiveness against the main periodontopathogens, has a significant immunomodulatory effect in the inflammatory process of periodontitis to be taken into account in the clinical decision to treat this disease.


REFERENCES

  1. Olsen I. From the Acta Prize Lecture 2014: the periodontal-systemic connection seen from a microbiological standpoint. Acta Odon-tol Scand. 2015 Aug;73(8):563-8.

  2. Polepalle T, Moogala S, Boggarapu S, Pesala DS, Palagi FB. Acute Phase Proteins and Their Role in Periodontitis: A Review. J Clin Diagn Res. 2015 Sept;9(11):ZE01-5.

  3. Graves DT, Cochran D. The contribution of interleukin-1 and tumor necrosis factor to periodontal tissue destruction. J Periodontol. 2003 Mar;74(3):391-401.

  4. Garcia Canas P, Khouly I, Sanz J, Loomer PM. Effectiveness of systemic antimicrobial thera-py in combination with scaling and root plan-ing in the treatment of periodontitis: a sys-tematic review. J Am Dent Assoc. 2015 Mar;146(3):150-63.

  5. Ardila CM, Martelo-Cadavid JF, Boderth-Acosta G, Ariza-Garcés AA, Guzmán IC. Ad-junctive moxifloxacin in the treatment of gen-eralized aggressive periodontitis patients: clinical and microbiological results of a ran-domized, triple-blind and placebo-controlled clinical trial. J Clin Periodontol. 2015 Feb;42(2):160-8.

  6. Ardila CM, Fernández N, Guzmán IC. Antimi-crobial susceptibility of moxifloxacin against gram-negative enteric rods from Colombian patients with chronic periodontitis. J Perio-dontol. 2010 Feb;81(2):292-9.

  7. Bode C, Diedrich B, Muenster S, Hentschel V, Weisheit C, Rommelsheim K et al. Antibiotics regulate the immune response in both pres-ence and absence of lipopolysaccharide through modulation of Toll-like receptors, cy-tokine production and phagocytosis in vitro. Int Immunopharmacol. 2014 Jan;18(1):27-34.

  8. Zimmermann GS, Neurohr C, Villena-Hermoza H, Hatz R, Behr J. Anti-inflammatory effects of antibacterials on hu-man bronchial epithelial cells. Respir Res. 2009 Sep 29;10:898.

  9. Araujo FG, Slifer TL, Remington JS. Effect of moxifloxacin on secretion of cytokines by hu-man monocytes stimulated with lipopolysac-charide. Clin Microbiol Infect. 2002 Jan;8(1):26-30.

  10. Giamarellos-Bourboulis EJ, Douzinas EE, Tsaganos T, Pagoulatou A, Livaditi O, Vafi-adou M et al. Cerebrospinal fluid of patients administered moxifloxacin modulates the secretion of cytokines from human mono-cytes. Diagn Microbiol Infect Dis. 2009 Jan;63(1):62-9.

  11. Müller HP, Holderrieth S, Burkhardt U, Höf-fler U. In vitro antimicrobial susceptibility of oral strains of Actinobacillus actinomycetem-comitans to seven antibiotics. J Clin Perio-dontol. 2002 Aug;29(8):736-42.

  12. Williams AC, Galley HF, Watt AM, Webster NR. Differential effects of three antibiotics on T helper cell cytokine expression. J Anti-microb Chemother. 2005 Sep;56(3):502-6.

  13. Hall IH, Schwab UE, Ward ES, Ives TJ. Ef-fects of moxifloxacin in zymogen A or S. au-reus stimulated human THP-1 monocytes on the inflammatory process and the spread of infection. Life Sci. 2003 Oct 10;73(21):2675-85.

  14. Beisswenger C, Honecker A, Kamyschnikow A, Bischoff M, Tschernig T, Bals R. Moxiflox-acin modulates inflammation during murine pneumonia. Respir Res. 2014 Jul 17;15:82.

  15. Shalit I, Kletter Y, Halperin D, Waldman D, Vasserman E, Nagler A. Immunomodulatory effects of moxifloxacin in comparison to ciprofloxacin and G-CSF in a murine model of cyclophosphamide- induced leukopenia. Eur J Haematol. 2001 May;66(5):287-96.

  16. Li H, Zhu S, He S, Hao L. Anti-inflammatory effects of moxifloxacin on rat airway smooth muscle cells exposed to allergen : Inhibition of extracellular-signal-regulated kinase and nuclear factor- k B activation and of inter-leukin-8 and eotaxin synthesis. Respirology. 2012 Aug;17(6):997-1005.

  17. Fabian I, Reuveni D, Levitov A, Halperin D, Priel E, Shalit I. Moxifloxacin enhances anti-proliferative and apoptotic effects of etopo-side but inhibits its proinflammatory effects in THP-1 and Jurkat cells. Br J Cancer. 2006 Oct 23;95(8):1038-46.

  18. Blau H, Klein K, Shalit I, Halperin D, Fabian I. Moxifloxacin but not ciprofloxacin or azithromycin selectively inhibits IL-8 , IL-6 , ERK1 / 2 , JNK , and NF- κ B activation in a cystic fibrosis epithelial cell line. Am J Physiol Lung Cell Mol Physiol. 2007 Jan;292(1):L343-52.

  19. Shalit I, Halperin D, Haite D, Levitov A, Ro-mano J, Osherov N, et al. Anti-inflammatory effects of moxifloxacin on IL-8, IL-1 b and TNFα secretion and NF k B and MAP-kinase activation in human monocytes stimulated with Aspergillus fumigatus. J Antimicrob Chemother. 2006 Feb;57(2):230-5.

  20. Choi JH, Song MJ, Kim SH, Choi SM, Lee DG, Yoo JH. Effect of Moxifloxacin on Production of Proinflammatory Cytokines from Human Peripheral Blood Mononuclear Cells. Antimi-crob Agents Chemother. 2003 Dec;47(12):3704-7.

  21. Wiesner G, Braun SL, Gruber M, Gertler R, Lange R, Tassani P. Neither moxifloxacin nor cefuroxime produces significant attenuation of inflammatory mediator release in patients exposed to cardiopulmonary bypass: a ran-domized controlled trial. J Antimicrob Chemo-ther. 2012 Jan;67(1):230-3.

  22. Ochoa Ramírez LA. Evaluación del efecto de antibióticos quinolónicos de nueva generación e immunepotent CRP sobre el Sistema inmu-ne. México: Facultad de Ciencias Biológicas. Universidad Autónoma de Nuevo León; 2011.

  23. Singh S, Kubler A, Singh UK, Singh A, Gardi-ner H, Prasad R. Metalloproteinases in a Cel-lular Model of Pulmonary Tuberculosis. Anti-microb Agents Chemother. 2014 Aug;58(8):4657-65.

  24. Martínez FJ. Monotherapy versus Dual Thera-py for Community-Acquired Pneumonia in Hospitalized Patients. Clin Infect Dis. 2004 May 15;38 Suppl 4:S328-40.

  25. Shalit I, Horev-Azaria L, Fabian I, Blau H, Kariv N, Shechtman I, et al. Immunomodula-tory and Protective Effects of Moxifloxacin against Candida albicans -Induced Broncho-pneumonia in Mice Injected with Cyclophos-phamide. Antimicrob Agents Chemother. 2002 Aug;46(8):2442-9.

  26. Fávaro WJ, Nunes OS, Seiva FR, Nunes IS, Woolhiser LK, Durán N. Effects of P-MAPA Immunomodulator on Toll-Like Receptors and p53 : Potential Therapeutic Strategies for Infectious Diseases and Cancer. Infect Agent Cancer. 2012 Jun 18;7(1):14.

  27. Dalhoff A, Shalit I. Immunomodulatory ef-fects of quinolones. Lancet Infect Dis. 2003 Jun;3(6):359-71.

  28. Kazama I, Nakajima T. Dual infection of My-coplasma pneumoniae and Chlamydophila pneumoniae predispositions successfully treated by moxifloxacin. Infez Med. 2014 Mar;22(1):41-7.

  29. Haffajee AD, Socransky SS, Gunsolley JC. Systemic anti-infective periodontal therapy. A systematic review. Ann Periodontol. 2003 Dec;8(1):115-81.

  30. Mestnik MJ, Feres M, Figueiredo LC, Soares G, Teles RP, Fermiano D, et al. The effects of adjunctive metronidazole plus amoxicillin in the treatment of generalized aggressive peri-odontitis: A 1-year double-blinded, placebo-controlled, randomized clinical trial. J Clin Periodontol. 2012 Oct;39(10):955-61.

  31. Xajigeorgiou C, Sakellari D, Slini T, Baka A, Konstantinidis A. Clinical and microbiologi-cal effects of different antimicrobials on gen-eralized aggressive periodontitis. J Clin Perio-dontol. 2006 Apr;33(4):254-64.

  32. Haas AN, Silva-Boghossian CM, Colombo AP, Susin C, Albandar JM, Oppermann RV, et al. Adjunctive azithromycin in the treatment of aggressive periodontitis: Microbiological find-ings of a 12-month randomized clinical trial. J Dent. 2012 Jul;40(7):556-63.

  33. Sampaio E, Rocha M, Figueiredo LC, Faveri M, Duarte PM, Gomes Lira EA, et al. Clinical and microbiological effects of azithromycin in the treatment of generalized chronic periodontitis: A randomized placebo-controlled clinical trial. J Clin Periodontol. 2011 Sep;38(9):838-46.

  34. Keestra JA, Grosjean I, Coucke W, Quirynen M, Teughels W. Non-surgical periodontal therapy with systemic antibiotics in patients with untreated aggressive periodontitis: a systematic review and meta-analysis. J Perio-dontal Res. 2015 Dec;50(6):689-706.




2020     |     www.medigraphic.com